Kornimate/medical-research-clean huggingface dataset:
mandibular angle fracture and interframents gap

Conditions: Mandibular Fractures

Summary: twenty-five patients with mandibular angle fracture were subjected to reduction and fixation through intra-oral open reduction and semi-rigid min plate fixation near the superior border of the mandible at champy's osteosynthesis line. the linear inter-fragmentary gap was measured at the inferior border of the mandible after fixation of the fractured bony segments in the final aligned position immediately postoperative on a panoramic radiograph for the mesio-distal plane and a cone beam computed tomography for the bucco-lingual plane to assess any lingual splay. the healing process was clinically followed for 3 months postoperatively for any complications and/or patient complains


Eligibility criteria:
inclusion criteria: * minimally displaced mandibular angle fracture which needed intervention via reduction and fixation \*medically free exclusion criteria: * - patients with multiple mandibular fractures or patients with concomitant maxillary fracture. * patients with severely displaced mandibular angle fracture needing extra-oral open reduction and fixation. * medically compromised patients and patients with abnormalities that impair bone healing
the effect of vitamin d replacement therapy on serum leptin and follicular growth pattern in women with resistant polycystic ovary

Conditions: Polycystic Ovary Syndrome

Summary: the study included 100 female diagnosed with polycystic ovary syndrome. they were classified into 2 groups: study group included 50 women will receive 300.000 i.u single dose of vitamin d intramuscular injection (memphis company) , and in the next menstrual cycle induction done by clomiphen citrate 100mg daily for 5 days starting from third day of menstruation and hmg single dose on 8th day . control group included 50 women will receive only clomiphen citrate 100mg daily for 5 days starting from third day of menstruation and hmg single dose on 8th day. serum 25 hydroxy vitamin d3, serum leptin and fsh will be done to all women before and after intervention.

the study included 100 female diagnosed with polycystic ovary syndrome diagnosed by by presence of 2 out of 3 criteria (according to eshre/asrm in rotterdam in 2003): oligoovulation and/or an ovulation , excess androgen activity (clinical or biochemical) and polycystic ovaries (by pelvic ultrasound "vaginal route").they were classified into 2 groups: study group included 50 women will receive 300.000 i.u single dose of vitamin d intramuscular injection (memphis company) , and in the next menstrual cycle induction done by clomiphen citrate 100mg daily for 5 days starting from third day of menstruation and hmg single dose on 8th day . control group included 50 women will receive only clomiphen citrate 100mg daily for 5 days starting from third day of menstruation and hmg single dose on 8th day. serum 25 hydroxy vitamin d3, serum leptin and fsh will be done to all women before and after intervention.

Eligibility criteria:
inclusion criteria: 1- bmi: more than 25.0 kg/m2 2- pco was diagnosed by presence of 2 out of 3 criteria (according to eshre/asrm in rotterdam in 2003) 1. oligoovulation and/or an ovulation 2. excess androgen activity (clinical or biochemical) 3. polycystic ovaries (by pelvic ultrasound "vaginal route") 3- anovulatory patient resistant to induction with clomiphene citrate alone exclusion criteria: -1) bmi: more than 35.0 kg/m2 2) infertile women due to any factor other than pco
"underwater" technique with submucosal solution of viscose solution -sic 8000 (eleviewtm) - for endoscopic resection of cole-rectal polyps with signs of fibrosis.

Conditions: Colo-rectal Polyps

Summary: all procedures are performed in the investigator's outpatient gastroenterology and digestive endoscopy unit by experienced endoscopists in conventional mucosectomies of the lower intestinal tract. before the procedure each patient, a normal endoscopic procedure. at the site of the lesion the lumen will be completely decompressed with aspiration of the gas, and then again relaxed with the instillation of only water. the eleviewtm will be injected into the submucosa in such quantities as to obtain a satisfactory lift of the lesion. the lesion will then be removed with a diathermic loop, preferably en-bloc, and in any case up to macroscopic evidence of complete resection. all the removed material will be stored and sent to histological analysis. tolerability score will be recorded during the procedure. any "bleeding" (both intra- and post-procedural), perforation, post-polypectomy syndrome, stenosis or death in the 6 months following the procedure will be born "complication". a surveillance colonoscopy including biopsy sampling of the research site scheduled 6 months after the procedure


Eligibility criteria:
inclusion criteria: * age\> 18 years. * signing of informed consent. * possibility of being subjected to the diagnostic and therapeutic procedures of the study. * presence of colo-rectal polypoid lesions ≥ 15mm presenting macroscopic aspects of fibrosis as a consequence of previous incomplete treatments or biopsies or relapses after previous removal. exclusion criteria: * highly indicative morphological characteristics of carcinoma with submucosal invasion (ulceration, pit pattern vn according to kudo et al.18) * pregnancy or breastfeeding * asa\> 3 * unstable personality or unable to adhere to the protocol procedures. * inability to provide informed consent. * injury not reachable endoscopically.
young, empowered & strong (yes): the young women's breast cancer study 2- focus on intervention pilot

Conditions: Breast Cancer

Summary: this research study is piloting a new internet-based research tool (yes portal). the main purpose of this pilot study is to test the web-based interface.

this study is being done to pilot a web-based research intervention tool. the investigators hope that by piloting it with the participants they can improve the tool and the other processes. the main purpose of this pilot study is to test the web-based interface, the participant's engagement with the platform, and the recruitment procedures. this initial pilot study will inform the design of a larger study intended to monitor common symptoms and behavior, and to provide supportive care information and research opportunities in an iterative manner for young women who have been diagnosed with breast cancer using the yes portal, built for smartphones, tablets, and computers.

Eligibility criteria:
inclusion criteria: * female * between the ages of 18-44 years * a history of breast cancer; we will pilot in 3 separate cohorts consisting of 10 patients each: newly diagnosed patients receiving care at dfci, prevalent survivors who have completed early active therapy (surgery, chemotherapy and/or radiotherapy) and are being followed at dfci, and women living with advanced breast cancer receiving care at dfci * be fluent in and able to read english * have internet access on a regular basis at the time of consent that can support the web-based platform exclusion criteria: n/a

Keywords: breast cancer
autologous bmmncs combined with educational intervention for asd

Conditions: Autism Spectrum Disorder

Summary: the purpose of this study is to evaluate the safety and effectiveness of autologous bone marrow mononuclear cell infusion combined with educational intervention for children with autism spectrum disorder (asd). inclusion criteria: male/female patients diagnosed with autism disorder based on dsm-v scale, the patient is between 3 to 7 years old, a patient has a medium level to server level of autism (cars score\>=30 to \ =50, patient's parent or caregiver must have the educational level of high school or above, patient's family has given consent to participate in the study. exclusion criteria for treatment group: patient above seven years of age and smaller than 3-year old, autistic patients having epilepsy, hydrocephalus with ventricular drain, allergy to anesthetic agents, severe health conditions such as cancer, failure of heart, lung, liver, or kidney, active infections, children with birth defects of the spine.

a total of 54 patients with autism spectrum disorder (aged 3-7) will be recruited and divided into two groups: the control group (only intervention education) (n = 27) and the treatment group (bone marrow mononuclear cell transplantation combined intervention education (n =27). the bone marrow mononuclear cell will be applied to 27 patients in the treatment group infuse via the intrathecal administration. the primary outcome is measured by the number of aes/saes during bmmncs infusion. the secondary outcome was measured by clinical examinations performed at baseline and then at 02, 06, and 12 months after the first infusion. multiple tools were used to diagnose and determine the severity of asd, including dsm-5, cars, the vineland adaptive behavior scales second edition (vabs-ii), and the clinical global impression (cgi). dsm-5, which was published in may 2013, provides new diagnostic criteria for asd

Eligibility criteria:
inclusion criteria: * patient is between 3 to 7 years old * male/female patient diagnosed with autism disorder according to the diagnostic criteria for autism spectrum disorder in diagnostic and statistical manual of mental disorders, fifth edition (dsm-5) * patient has a medium level to the most severe level of autism (cars score \>=34 to 50) * patient's parent or caregiver must have an educational level of high school or above * patient's family has given consent to participate in the study exclusion criteria: * patient is above seven years of age * autistic patient having epilepsy * patient with coagulation disorders * hydrocephalus with ventricular drain * allergy to anesthetic agents * sever health conditions such as cancer, failure of heart, lung, liver, or kidney * active infections
dynamics of the anti-factor viii antibody signature during treatment with emicizumab

Conditions: Severe Hemophilia A; Severe Hemophilia A With Inhibitor; Severe Hemophilia A Without Inhibitor

Summary: the goal of this observational study is to learn about the changes of antibodies and inhibitors against the coagulation factor viii in patients with severe hemophilia a receiving emicizumab therapy. no additional visits or procedures are planned. patients in this study will continue to receive their routine care and analysis will be done from left over samples from routine visits.


Eligibility criteria:
inclusion criteria: * severe congenital hemophilia a (cha) * treatment with emicizumab irrespective of any other treatment * informed consent exclusion criteria: * no therapy with emicizumab * immunosuppressive therapy * hiv-infection with cd4 (cluster of differentiation 4) cells \<200/µl
treatment of natural killer/t cell lymphoma-i/ii

Conditions: Nasal and Nasal-type NK/T-cell Lymphoma

Summary: the purpose of this study is to evaluate the efficacy and safety of ddgp regiment (gemcitabine，pegaspargase,cisplatin,dexamethasone) for patients with newly diagnosed stage i/ii natural killer (nk)/t cell lymphoma.

patients with nk/t cell lymphoma usually have a bad prognosis. these patients cannot be treated successfully with the conventional chemotherapy of chop. the investigators have been proceeding this trial to evaluate the efficacy and safety of the combination chemotherapy regiment ddgp (gemcitabine，pegaspargase, cisplatin, dexamethasone) in the patients with stage i/ii nk/t cell lymphoma.

Eligibility criteria:
inclusion criteria: * age range 14-70 years old; ecog performance status 0-2; estimated survival time \> 3 months * histological confirmed nk/t cell lymphoma * none of chemotherapy or radiotherapy has been previously used * none of chemotherapy contraindication: hemoglobin ≥ 90 g/dl, neutrophil ≥ 1.5×109/l, platelet ≥ 100×109/l, alt and ast ≤ 2×uln, serum bilirubin ≤ 1.5×uln, serum creatine ≤ 1.5×upper limitation of normal (uln), serum albumin ≥ 30g/l, serum plasminogen is normal (inclusion criteria of 1,3,6 groups ) * at least one measurable lesion * none of other serious diseases, cardiopulmonary function is normal * pregnancy test of women at reproductive age must be negative * patients could be followed up * none of other relative treatments including the traditional chinese medicine, immunotherapy,biotherapy except anti-bone metastasis therapy and other symptomatic treatments. * volunteers who signed informed consent. exclusion criteria: * disagreement on blood sample collection * patients allergic of any of drug in this regimen or with metabolic disorder * pregnant or lactating women * serious medical illness likely to interfere with participation * serious infection * primitive or secondary tumors of central nervous system * chemotherapy or radiotherapy contraindication * the evidence of cns metastasis * history of peripheral nervous disorder or dysphrenia * patients participating in other clinical trials * patients taking other antitumor drugs * patients estimated to be unsuitable by investigator

Keywords: nk/t cell lymphoma chemotherapy clinical trial rr pfs os
a study to evaluate the safety, pharmacokinetics, and activity of xmab24306 in combination with cevostamab in participants with relapsed/refractory multiple myeloma

Conditions: Multiple Myeloma

Summary: the purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and activity of xmab24306 in combination with cevostamab in participants with relapsed/refractory multiple myeloma (r/r mm) who have received a minimum of three prior treatments, including at least one immunomodulatory drug (imid), one proteasome inhibitor (pi), and one anti-cd38 monoclonal antibody.


Eligibility criteria:
inclusion criteria: * eastern cooperative oncology group (ecog) performance status of 0 or 1 * life expectancy of at least 12 weeks * participants must have received a minimum of 3 prior lines of therapy, including at least one pi, one imid, and an anti-cd38 monoclonal antibody. * documented evidence of progressive disease on or after the last prior therapy, or participants who were intolerant to the last prior therapy. * measurable disease, as defined by the protocol * participants agree to follow contraception or abstinence requirements as defined in the protocol exclusion criteria: * any anti-cancer therapy within 3 weeks prior to initiation of study treatment with exception defined by the protocol * participants with autologous stem cell transplantation (sct) within 100 days prior to first dose of study treatment * participants with prior allogeneic sct or solid organ transplantation * known history of hemophagocytic lymphohistiocytosis (hlh) or macrophage activation syndrome (mas) * active or history of autoimmune disease * participants with current or history of central nervous system (cns) disease, or current cns involvement by multiple myeloma (mm) * significant cardiovascular disease * participants with known clinically significant liver disease * symptomatic active pulmonary disease requiring supplemental oxygen * known active infection requiring intravenous anti-microbial therapy within 14 days prior to first study drug administration * any episode of active, symptomatic covid-19 infection, or requiring treatment with iv antivirals for covid-19 (not including covid-19 primary prophylaxis) within 14 days, prior to first study treatment * other protocol defined inclusion/exclusion criteria may apply
trial of alpha one antitrypsin inhalation in treating patient with severe acute respiratory syndrome coronavirus 2 (sars-cov-2)

Conditions: Coronavirus

Summary: it is clear now that sars-cov-2 could use angiotensin-converting enzyme 2 (ace2), the same receptor as sars-cov transmembrane protease serine type 2 (tmprss2), a protease belonging to the type ii transmembrane serine protease family, cleaves the coronavirus spike protein serine proteases are inhibited by a diverse group of inhibitors, the best-studied serpins are antithrombin and alpha 1-antitrypsin


Eligibility criteria:
inclusion criteria: 1. positive rt-pcr) assay for sars-cov-2 2. age \>18 years 3. hospitalized 4. able to give informed consent exclusion criteria: 1. known allergy to aat 2. imminent death within next 24 hours
readiness for behavior change after a heart attack

Conditions: Myocardial Infarction; Stable Angina; Coronary Artery Disease

Summary: the purpose of this study is to test if an early appointment (within 10 days) when compared to a standard appointment (5 weeks) will affect attendance at the cardiac rehabilitation orientation and subsequent enrollment into cardiac rehabilitation.

cardiac rehabilitation is central to full recovery after a myocardial infarction or a cardiac stenting procedure. yet, this therapy is underutilized across the nation. henry ford currently enrolls about 42% of eligible patients. in addition, it currently takes, on average, 42 +/-26 days from hospital discharge to enrollment in rehabilitation. during this delay, there is strong tendency to return to prior habits (sedentary lifestyle, smoking, poor nutrition, etc.) that led to the myocardial infarction in the first place. this delay is both 1) unnecessary and 2) probably harmful to the patients' readiness to make changes. the investigators seek to perform a randomized controlled trial of early (7-10 days) vs standard referral (5-6 weeks) to cardiac rehabilitation. in addition, the investigators will examine the patients' readiness to change through the first 3 months of the post-hospitalization period and correlate that to their behavior and enrollment in cardiac rehabilitation. assessment of readiness to change will be accomplished by serial survey's, which will be administered at discharge, 2 weeks, 5 weeks, and 13 weeks after discharge. patients will consent to take the survey and be observed in a clinical study. however, in order to avoid the hawthorne effect, patients they will not initially be aware of the primary hypothesis, as the investigators strongly believe this will affect the main behavior they are trying to measure. full patient disclosure will occur at the end of the trial.

Eligibility criteria:
inclusion criteria: * stable angina * myocardial infarction * percutaneous coronary intervention * willingness to participate and consent for medical record review * willingness to complete survey's exclusion criteria: * recent illicit drug use * unstable psychiatric condition * moderate or severe dementia * inability to follow-up * leaving system with plans to enroll in cardiac rehabilitation out-of-system * inability to exercise (amputee, severe claudication) * unstable medical condition that would prevent regular exercise training * uncorrected severe aortic stenosis or severe mitral stenosis * referring physician feels that exercise is contra-indicated due to safety or other patient specific factors * cabg, lvad, or heart transplant

Keywords: cardiac rehabilitation referral enrollment timing
real-life treatment outcomes of ravulizumab in pnh

Conditions: Paroxysmal Nocturnal Haemoglobinuria

Summary: the pnh-record study, a polish multicenter observational (non-interventional), open-label, retrospective with prospective follow-up.

pnh-record study aims to aims to collect data on the patients' characteristics and clinical outcomes of ravulizumab administered in the scope of routine clinical practice in pnh.

Eligibility criteria:
inclusion criteria: 1. adult (aged ≥18) patients with pnh receiving ravulizumab treatment in the frames of ndp in poland. 2. patients willing to participate in the study and signed icf. exclusion criteria: 1. those who participated in ravulizumab clinical trial in the past, and/or those who participated/plans to participate in clinical trial on/after the date of first ravulizumab infusion through ndp. 2. cognitive incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.

Keywords: paroxysmal nocturnal haemoglobinuria pnh ravulizumab
effect of some drugs on liver fibrosis

Conditions: Liver Fibroses

Summary: effect of some drugs on liver fibrosis

the study aimed at evaluating the effect of some drugs on liver fibrosis

Eligibility criteria:
inclusion criteria: * chronic hepatitis c exclusion criteria: * acute hepatitis * thalassemia
atorvastatin reduces chronic inflammation and average epogen dose (archived)

Conditions: Complication of Renal Dialysis

Summary: the specific aim of this trial is to determine whether initiating moderate- or high-intensity atorvastatin therapy in hemodialysis patient not previously on a statin reduces inflammation and lowers average epogen utilization. statin naive patients on maintenance hd will be started on 20mg atorvastatin daily for weeks and then titrated up to 40mg atorvastatin daily for an additional 12 weeks. patient's inflammatory markers (ferritin, crp) and weekly epogen usage will be monitored.

patients will be identified and consented. after informed consent is obtained, baseline demographic information, past medical history, dialysis specific information, and laboratory metrics (lipid profile, inflammatory markers) will be obtained from the electronic medical records. for the first 12 weeks, all subjects will be instructed to take one 20mg atorvastatin tablet daily; atorvastatin tablets will be dispensed by the research team in 30-tablet increments every month to ensure compliance and prevent diversion. subjects will undergo standard-of-care hemodialysis with routine hemoglobin monitoring and epogen titration according to the dialysis center protocol. every two weeks, they will be assessed by a research coordinator who will monitor for medication adverse effects (see attached patient survey) and medication compliance (pill counts) at alternating visits. after 12 weeks, lipid profile and inflammatory markers will be rechecked or obtained from the electronic medical record. for the subsequent 12 weeks (ie. weeks 12-24), subjects will be instructed to take two 20mg atorvastatin tablets (40mg total) daily. if the subject is unable to tolerate 40mg of atorvastatin daily due to medication adverse effects, they will continue to take 20mg atorvastatin daily for the remainder of the trial. epogen will be titrated and subjects will be monitored as above. at the completion of the study, a lipid panel and inflammatory markers will be checked for a third time. epogen usage and dialysis specific information will be recorded continuously throughout the study.

Eligibility criteria:
inclusion criteria: * stable on hemoglobin levels on epogen therapy (hgb between 9.5-11.5 for prior 3 weeks) * no statin usage during the prior 3 months * complaint with hemodialysis and medications exclusion criteria: * prior history of myocardial infarction, stroke or vascular disease * prior hospitalization within the past 15 days * prior episodes of significant bleeding (trauma, gi bleed, gu bleed, menorrhagia) in the prior 15 days * liver disease * active malignancy * hematologic disorder